Literature DB >> 21696765

Reoperative completion pancreatectomy for suspected malignant disease of the pancreas.

Harish Lavu1, Leonard J Nowcid, Matthew J Klinge, Krishnaraj Mahendraraj, Dane R Grenda, Patricia K Sauter, Ernest L Rosato, Eugene P Kennedy, Charles J Yeo.   

Abstract

BACKGROUND: Completion pancreatectomy (CP) is a reoperative procedure to excise remnant pancreatic tissue after a prior pancreatic resection. In this study, we document our institution's experience with CP for recurrent malignant disease of the pancreas, describing indications for surgery, procedures performed, and patient outcomes.
METHODS: We performed a retrospective review of 861 patients from the pancreatic surgery database in the Department of Surgery of Thomas Jefferson University from October 2005 to December 2010 to identify all cases of CP performed for suspected malignant disease.
RESULTS: Eleven patients underwent reoperative CP at our institution from 2005 to 2010. The median time interval between the initial operation and CP was 32 mo. A combination of clinical symptoms, elevated tumor markers, and imaging studies were used for diagnosis of recurrent disease. Pancreatic ductal adenocarcinoma was the most common pathology, found in six patients. The postoperative complication rate was 18% and the median postoperative hospital length of stay was 6 d. There were no 30-d readmissions and no perioperative deaths. The 1-y survival rate following CP was 71% with an overall median survival of 17.5 mo.
CONCLUSIONS: CP is a safe and effective option for a highly selected group of patients with suspected recurrent malignant disease of the remnant pancreas. Morbidity and mortality rates are within acceptable limits and similar to initial pancreatic resection. Eligibility depends heavily upon the absence of distant metastatic disease, technical factors for resection, and patient performance status.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21696765     DOI: 10.1016/j.jss.2011.04.050

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  14 in total

1.  Pancreatic cancer arising from the remnant pancreas after pancreatectomy: a multicenter retrospective study by the Kyushu Study Group of Clinical Cancer.

Authors:  Daisuke Hashimoto; Kota Arima; Shigeki Nakagawa; Yuji Negoro; Toshihiko Hirata; Masahiko Hirota; Masafumi Inomata; Kengo Fukuzawa; Takefumi Ohga; Hiroshi Saeki; Eiji Oki; Yo-Ichi Yamashita; Akira Chikamoto; Hideo Baba; Yoshihiko Maehara
Journal:  J Gastroenterol       Date:  2018-12-04       Impact factor: 7.527

2.  Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection.

Authors:  Ryan M Thomas; Mark J Truty; Graciela M Nogueras-Gonzalez; Jason B Fleming; Jean-Nicolas Vauthey; Peter W T Pisters; Jeffrey E Lee; David C Rice; Wayne L Hofstetter; Robert A Wolff; Gauri R Varadhachary; Huamin Wang; Matthew H G Katz
Journal:  J Gastrointest Surg       Date:  2012-05-30       Impact factor: 3.452

3.  Aggressive secondary surgery for local recurrence of pancreatic cancer.

Authors:  Norihiro Shimoike; Takahisa Fujikawa; Hisatsugu Maekawa; Akira Tanaka
Journal:  BMJ Case Rep       Date:  2013-06-16

4.  Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration.

Authors:  Mark J Truty; Ryan M Thomas; Matthew H Katz; Jean-Nicolas Vauthey; Christopher Crane; Gaury R Varadhachary; Robert A Wolff; James L Abbruzzese; Jeffrey E Lee; Jason B Fleming
Journal:  J Am Coll Surg       Date:  2012-05-18       Impact factor: 6.113

5.  Emergency pancreatic surgery--demanding and dangerous.

Authors:  Oliver Strobel; Lutz Schneider; Sebastian Philipp; Stefan Fritz; Markus W Büchler; Thilo Hackert
Journal:  Langenbecks Arch Surg       Date:  2015-07-07       Impact factor: 3.445

6.  Multimodality treatment of recurrent pancreatic cancer: Mith or reality?

Authors:  Cosimo Sperti; Lucia Moletta; Stefano Merigliano
Journal:  World J Gastrointest Oncol       Date:  2015-12-15

7.  Preoperative imaging for resectable periampullary cancer: clinicopathologic implications of reported radiographic findings.

Authors:  Zhi Ven Fong; Wei Phin Tan; Harish Lavu; Eugene P Kennedy; Donald G Mitchell; Leonidas G Koniaris; Patricia K Sauter; Ernest L Rosato; Charles J Yeo; Jordan M Winter
Journal:  J Gastrointest Surg       Date:  2013-04-04       Impact factor: 3.452

8.  The investigation of the survival time after recurrence in patients with pancreatic ductal adenocarcinoma for individualization of adjuvant chemotherapy.

Authors:  Daisaku Yamada; Hidetoshi Eguchi; Yoshifumi Iwagami; Tadafumi Asaoka; Takehiro Noda; Koichi Kawamoto; Kunihito Gotoh; Shogo Kobayashi; Masaki Mori; Yuichiro Doki
Journal:  Surg Today       Date:  2018-05-17       Impact factor: 2.549

Review 9.  Completion pancreatectomy for recurrent pancreatic cancer in the remnant pancreas: report of six cases and a review of the literature.

Authors:  Yasuo Shima; Takehiro Okabayashi; Akihito Kozuki; Tatsuaki Sumiyoshi; Teppei Tokumaru; Yuichi Saisaka; Keiichi Date; Jun Iwata
Journal:  Langenbecks Arch Surg       Date:  2015-11-06       Impact factor: 3.445

10.  Resection of metachronous pancreatic cancer 4 years after pancreaticoduodenectomy for stage III pancreatic adenocarcinoma.

Authors:  John B Hamner; Michael White; Carly Crowder; Gagandeep Singh
Journal:  World J Surg Oncol       Date:  2015-09-30       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.